<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386682</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol CLIN PMI-002</org_study_id>
    <nct_id>NCT03386682</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Performance of ESTYME® MATRIX Round and Anatomical Breast Implants - EMMIE Study</brief_title>
  <acronym>EMMIE</acronym>
  <official_title>Evaluation of the Safety and Performance of SYMATESE AESTHETICS ESTYME® MATRIX Round and Anatomical Silicone Gel-Filled Breast Implants in the Breast Augmentation and Reconstruction - EMMIE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symatese Aesthetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedPass International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Symatese Aesthetics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety and performance of the ESTYME® MATRIX Round and Anatomical
      Silicone Gel-Filled Breast Implants in the breast augmentation and reconstruction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the safety and performance of the ESTYME® MATRIX Round and Anatomical
      Silicone Gel-Filled Breast Implants in the breast augmentation and reconstruction at 3
      months, 1 year and 2 years post-procedure
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 23, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local complications</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of the safety 3 months post-implantation.
Procedure-related adverse events/complications at 3 months post implant. Main foreseen complications: infection, haematoma, wound healing complication, fluid accumulation, early capsular contracture, rupture, extrusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction of the patient and the surgeon</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of the performance, 3 months post-implantation
Performance endpoint will be assessed by implant procedure success at 3 months defined as follows:
satisfactory procedure duration for the surgeon
satisfactory size of the incision for the surgeon
implant correct placement (absence of visible deformation of the gel, absence of rotation for anatomical implants)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local complications</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Evaluation of the safety, 1 year and two years post-implantation.
Safety endpoint: incidence of all Adverse Events (AE)/Serious Adverse Events (SAEs) @ 1 year and two years post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of the patient and the surgeon</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Performance endpoints are as follows:
global surgeon satisfaction post-procedure assessed by the usability of the device during the procedure (current implant procedure): surgeon comfort level for the insertion/implantation of the prosthesis,
global patient and surgeon satisfaction @ 1 year and 2 years post-procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Breast Augmentation</condition>
  <condition>Breast Reconstruction</condition>
  <arm_group>
    <arm_group_label>ESTYME MATRIX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who meet the requirements for breast augmentation or breast reconstruction surgeries and have been implanted with one or two ESTYME® MATRIX Breast Implant(s)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ESTYME® MATRIX Breast Implants</intervention_name>
    <description>Breast implant surgery in breast reconstruction or breast augmentation</description>
    <arm_group_label>ESTYME MATRIX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient will be included if all of the following criteria are met:

          1. Subject of between 18 and 65 years old

          2. Candidate eligible for :

             a. unilateral or bilateral breast augmentation i. general breast enlargement: cosmetic
             purposes, providing symmetry to opposite breast in case of unilateral surgery ii.
             surgical correction of various congenital or acquired anomalies such as amastia,
             aplasia, hypomastia, hypoplasia, asymmetries, Poland's syndrome, ptosis …

             b. or immediate or delayed unilateral or bilateral breast reconstruction (for cancer,
             trauma, surgical loss of breast)

          3. Patient signs PIC (Patient Informed Consent) &amp; willing to comply with the protocol
             assessments and visits follow up

        Exclusion Criteria:

        Patient will not be included if any of the following conditions exists:

          1. Local or systemic infection or abscess anywhere in the body

          2. Existing carcinoma or pre-carcinoma of the breast without treatment or mastectomy
             treatment without appropriate wash out period for chemotherapy at the surgeon
             discretion

          3. Subject with previous tissue expansion

          4. Diagnosis of active cancer of any type for augmentation procedure subject

          5. Pregnant subject or intending to become pregnant within three (3) months of the
             implant procedure

          6. Subject who had nursed within three (3) months of implant surgery, or still
             breastfeeding

          7. Tissue characteristics determined clinically inadequate or unsuitable by the surgeon
             (i.e. tissue damage resulting from radiation, inadequate tissue or compromised
             vascularity, know complication wound healing)

          8. Previously implanted subject with a silicone implant or History of failure following
             cosmetic augmentation or subcutaneous mastectomy

          9. History of autoimmune disease such as but not limited to: lupus, scleroderma …

         10. Any condition or treatment for any condition which, in the opinion of the physician,
             may constitute an unwarranted surgical risk (e.g. anaesthesia allergy, high
             consumption smoking subject …)

         11. Anatomic or physiologic abnormality which could result to significant post-operative
             complications

         12. History of sensitivity of foreign materials or known allergy to any component of the
             ESTYME® MATRIX Silicone Gel-Filled Breast Implant

         13. Subject known for alcohol abuse/history

         14. Underlying disease (HIV positive Subject, HF (heart Failure), renal insufficiency,
             diabetes, hypertension, …)

         15. Subject with implanted metal or metal devices, history of claustrophobia, or other
             condition that would make a MRI scan prohibitive

         16. Unwilling to undergo any further surgery for revision

         17. Subject with willingness that are unrealistic/unreasonable with the risks involved
             with the surgical procedure

         18. Participating into any other clinical study or had participated into a clinical study
             without appropriate wash out period at the surgeon discretion

         19. Subject who has sociological, cultural or geographical factors which could interfere
             with evaluation or completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EMMANUEL DELAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Charcot</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre F.X. Michelet Chu Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Charcot</name>
      <address>
        <city>Sainte-Foy-lès-Lyon</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

